BEIGENE, LTD. Financials BeiGene, Ltd. Deutsche Boerse AG
Equities
49B
KYG1146Y1017
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.85 EUR | -1.25% |
|
+0.87% | -6.45% |
| 06:13am | Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India | MT |
| 14/05 | BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,134 | 23,494 | 27,843 | 22,843 | 18,862 | 18,230 | - | - |
| Enterprise Value (EV) 1 | 9,392 | 19,361 | 24,097 | 19,511 | 16,564 | 16,644 | 17,209 | 16,826 |
| P/E ratio | -10.5 x | -13.5 x | -17.8 x | -11.3 x | -21.3 x | -19.3 x | -44.7 x | 85.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.7 x | 76.1 x | 23.7 x | 16.1 x | 7.67 x | 5.66 x | 4.53 x | 3.61 x |
| EV / Revenue | 21.9 x | 62.7 x | 20.5 x | 13.8 x | 6.74 x | 5.17 x | 4.27 x | 3.33 x |
| EV / EBITDA | -9.98 x | -11.9 x | -17.3 x | -11.3 x | -14.8 x | -21.3 x | -59.3 x | 44.1 x |
| EV / FCF | -11.2 x | -13.8 x | -15.4 x | -10.7 x | -9.63 x | -21.2 x | -41.6 x | 47.4 x |
| FCF Yield | -8.94% | -7.24% | -6.48% | -9.34% | -10.4% | -4.72% | -2.4% | 2.11% |
| Price to Book | 11.2 x | 5.57 x | 4.03 x | 5.17 x | 5.32 x | 6.46 x | 6.88 x | 5.43 x |
| Nbr of stocks (in thousands) | 61,136 | 90,924 | 1,02,770 | 1,03,859 | 1,04,578 | 1,04,579 | - | - |
| Reference price 2 | 165.8 | 258.4 | 270.9 | 219.9 | 180.4 | 174.3 | 174.3 | 174.3 |
| Announcement Date | 02/03/20 | 25/02/21 | 25/02/22 | 27/02/23 | 26/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 428.2 | 308.9 | 1,176 | 1,416 | 2,459 | 3,220 | 4,027 | 5,055 |
| EBITDA 1 | -941.3 | -1,626 | -1,392 | -1,723 | -1,120 | -782.7 | -290.2 | 381.6 |
| EBIT 1 | -959.9 | -1,658 | -1,439 | -1,790 | -1,208 | -958.3 | -448.7 | 245.2 |
| Operating Margin | -224.16% | -536.69% | -122.31% | -126.4% | -49.12% | -29.76% | -11.14% | 4.85% |
| Earnings before Tax (EBT) 1 | -943.6 | -1,618 | -1,439 | -1,961 | -825.8 | -857.4 | -383.2 | 302.8 |
| Net income 1 | -948.6 | -1,597 | -1,413 | -2,004 | -881.7 | -868.9 | -359.9 | 218.5 |
| Net margin | -221.53% | -517.01% | -120.15% | -141.52% | -35.86% | -26.98% | -8.94% | 4.32% |
| EPS 2 | -15.80 | -19.13 | -15.23 | -19.43 | -8.450 | -9.017 | -3.899 | 2.048 |
| Free Cash Flow 1 | -839.9 | -1,401 | -1,562 | -1,822 | -1,719 | -786.3 | -413.6 | 354.7 |
| FCF margin | -196.14% | -453.57% | -132.76% | -128.68% | -69.93% | -24.42% | -10.27% | 7.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 92.94% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 162.31% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 02/03/20 | 25/02/21 | 25/02/22 | 27/02/23 | 26/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 214 | 420.4 | 306.6 | 341.6 | 387.6 | 380.1 | 606.4 | 447.8 | 595.3 | 1,043 | 781.3 | 634.4 | 751.7 | 783.2 | 860 | 861.2 | 798 | 961.6 |
| EBITDA 1 | -558.6 | - | -426.7 | -423.9 | -422.2 | -450.6 | - | -351.2 | - | - | -112.5 | -565.3 | -236.1 | -225.9 | -222.4 | -214.2 | -115.2 | -85.78 |
| EBIT 1 | -571.7 | - | -443.3 | -439.4 | -438.4 | -468.6 | -907 | -371.3 | -318.7 | -690 | -134 | -589.1 | -261.3 | -248.6 | -237.6 | -240.7 | -169.9 | -116.6 |
| Operating Margin | -267.19% | - | -144.57% | -128.64% | -113.09% | -123.29% | -149.56% | -82.91% | -53.54% | -66.15% | -17.15% | -92.86% | -34.77% | -31.75% | -27.63% | -27.95% | -21.29% | -12.12% |
| Earnings before Tax (EBT) 1 | -586.8 | - | -421.2 | -557.6 | -551.2 | -431 | -982.2 | -336.9 | -367.5 | -704.4 | 229.3 | -350.8 | -243.4 | -258.7 | -237.6 | -225.7 | -185.1 | -107.9 |
| Net income 1 | -585.7 | -999.5 | -434.3 | -571.4 | -557.6 | -445.3 | -998.1 | -348.4 | -381.1 | -729.6 | 215.4 | -367.6 | -251.2 | -255.8 | -234.8 | -222.1 | -185.1 | -107.9 |
| Net margin | -273.7% | -237.74% | -141.63% | -167.3% | -143.84% | -117.16% | -164.59% | -77.81% | -64.03% | -69.94% | 27.57% | -57.94% | -33.41% | -32.66% | -27.31% | -25.79% | -23.2% | -11.22% |
| EPS 2 | -6.160 | - | -4.240 | -5.560 | -5.390 | -4.290 | - | -3.340 | -3.640 | - | 2.010 | -3.480 | -2.410 | -2.453 | -2.248 | -2.121 | -1.810 | -1.050 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 25/02/22 | 25/02/22 | 05/05/22 | 04/08/22 | 09/11/22 | 27/02/23 | 27/02/23 | 04/05/23 | 02/08/23 | 02/08/23 | 09/11/23 | 26/02/24 | 08/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 742 | 4,132 | 3,746 | 3,332 | 2,297 | 1,586 | 1,021 | 1,404 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -840 | -1,401 | -1,562 | -1,822 | -1,719 | -786 | -414 | 355 |
| ROE (net income / shareholders' equity) | -70.2% | -66.1% | -28% | -38.1% | -22.3% | -26.7% | -12.4% | 12.3% |
| ROA (Net income/ Total Assets) | -49.1% | -44.3% | -19.8% | -26.9% | -14.5% | -17.5% | -8.35% | 6.18% |
| Assets 1 | 1,931 | 3,607 | 7,123 | 7,457 | 6,093 | 4,959 | 4,308 | 3,538 |
| Book Value Per Share 2 | 14.80 | 46.40 | 67.30 | 42.50 | 33.90 | 27.00 | 25.30 | 32.10 |
| Cash Flow per Share 2 | -12.50 | -15.40 | -14.00 | -14.50 | -11.10 | -5.300 | -1.900 | 5.300 |
| Capex 1 | 89.6 | 118 | 263 | 325 | 562 | 264 | 250 | 273 |
| Capex / Sales | 20.93% | 38.04% | 22.35% | 22.98% | 22.85% | 8.2% | 6.22% | 5.41% |
| Announcement Date | 02/03/20 | 25/02/21 | 25/02/22 | 27/02/23 | 26/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
174.3
USD
Average target price
267
USD
Spread / Average Target
+53.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.19% | 12TCr | |
| +13.03% | 11TCr | |
| -13.65% | 2.23TCr | |
| -3.99% | 2.16TCr | |
| -39.93% | 1.76TCr | |
| +7.35% | 1.43TCr | |
| +33.48% | 1.24TCr | |
| -28.25% | 828.11Cr | |
| +18.21% | 826.08Cr |
- Stock Market
- Equities
- BGNE Stock
- 49B Stock
- Financials BeiGene, Ltd.